This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
iver transplantation is presently the only proven therapy able to extend survival for end-stage liver disease. It is also the only
treatment for severe acute liver failure and to some forms of inborn errors of metabolism. Nevertheless, the waiting list for
liver transplantation is long and many patients will not survive long enough to receive an organ due to the dramatic shortage of
donors or lack of eligibility. This distressing donor shortage is also common to other solid organs like the lungs, heart and kidneys.
In light of the grim situation of liver organ transplantation, our laboratory has recently developed a method to generate an
entire liver organ scaffold from whole animal livers, using tissue decellularization that preserves the organ?s vascular network.
This same method, is also able to decellularize other solid organs generating specific acellular kidney, lung, intestine, pancreas or
heart scaffolds. Our subsequent studies showed the possibility to efficiently re-cellularize the liver bioscaffolds by perfusing them
with human fetal liver progenitor and endothelial cells in a perfusion bioreactor. The outcome was a bioengineered human liver.
The bioengineered human liver organoids displayed typical hepatic phenotypic markers and bile ducts, and some vital
human liver functions, such as drug metabolism, protein synthesis and catabolism. These results demonstrate the feasibility
of generating bioengineered human liver organoids using acellular organ scaffolds and primary human cells. Altogether, this
technology has the potential to create bioengineered organs, critical for stem cell and developmental biology, drug discovery and
toxicology, and ultimately, transplantation and treatment of terminal diseases
Pedro Baptista is a research fellow at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, USA. His main research interest is
in liver organ bioengineering and regeneration. From his work, resulted the development of the first human liver ever made in a laboratory, impacting
the scientific community at large and widely broadcasted in the media all around the world. His current research interests focus on investigating liver
stem cell biology and the development of novel methods to expand fetal and adult human stem cells to the required numbers necessary for organ
bioengineering. He is also interested in applying bioengineered organs to study developmental biology
, physiology and drug discovery
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals